SEVİK, M. O. Et Al. 2024. Real-life neovascular AMD treatment considering reimbursement in Turkiye: One-year comparison of switching to intravitreal ranibizumab or aflibercept after treatment failure with three loading intravitreal bevacizumab injections. Northern Clinics of Istanbul , vol.11, no.5 , 451-459.

SEVİK, M. O., TIRAŞ, N. Z., Aykut, A., DİZDAR YİĞİT, D., & ŞAHİN, Ö., (2024). Real-life neovascular AMD treatment considering reimbursement in Turkiye: One-year comparison of switching to intravitreal ranibizumab or aflibercept after treatment failure with three loading intravitreal bevacizumab injections. Northern Clinics of Istanbul , vol.11, no.5, 451-459.

SEVİK, MEHMET Et Al. "Real-life neovascular AMD treatment considering reimbursement in Turkiye: One-year comparison of switching to intravitreal ranibizumab or aflibercept after treatment failure with three loading intravitreal bevacizumab injections," Northern Clinics of Istanbul , vol.11, no.5, 451-459, 2024

SEVİK, MEHMET O. Et Al. "Real-life neovascular AMD treatment considering reimbursement in Turkiye: One-year comparison of switching to intravitreal ranibizumab or aflibercept after treatment failure with three loading intravitreal bevacizumab injections." Northern Clinics of Istanbul , vol.11, no.5, pp.451-459, 2024

SEVİK, M. O. Et Al. (2024) . "Real-life neovascular AMD treatment considering reimbursement in Turkiye: One-year comparison of switching to intravitreal ranibizumab or aflibercept after treatment failure with three loading intravitreal bevacizumab injections." Northern Clinics of Istanbul , vol.11, no.5, pp.451-459.

@article{article, author={MEHMET ORKUN SEVİK Et Al. }, title={Real-life neovascular AMD treatment considering reimbursement in Turkiye: One-year comparison of switching to intravitreal ranibizumab or aflibercept after treatment failure with three loading intravitreal bevacizumab injections}, journal={Northern Clinics of Istanbul}, year=2024, pages={451-459} }